Home / Market News / $APVO
fiscal.ai Corporate Catalyst Impact 75/100 ● neutral

Aptevo Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Progress

Nov 17, 2026, 2:29 PM UTC · Primary ticker $APVO

Aptevo Therapeutics reported a reduced net loss in Q3 2026 and significant clinical progress for its lead AML candidate, mipletamig, including a high remission rate and improved tolerability. The company also announced a new patent application and a strategic collaboration, indicating positive developments for its pipeline and future growth prospects.

Aptevo Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $6.5 million, an improvement from the prior year. The key highlight is the strong clinical progress of mipletamig, showing a 79% remission rate in a challenging AML patient population, which is a significant de-risking event for the drug. The new patent application and strategic collaboration with Niowave further bolster the company's long-term pipeline and potential for future revenue streams. This news is a positive catalyst for Aptevo, suggesting potential for increased investor confidence and stock appreciation in the short term, as it addresses both financial performance and critical pipeline development. The main opportunity for traders lies in the potential for mipletamig to advance successfully through trials and for the new technologies to generate value.

$APVO positive Positive clinical data, reduced loss, new patent, collaboration
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.